Thank you and all the best, from all of us at ACO!

Many significant advancements have been made recently in HIV vaccine research. However, statistics still show that approximately 2 million people continue to become infected and 1 million people continue to die from AIDS-related illnesses each year. An HIV vaccine is still needed to stop this epidemic. 

Since the establishment of the Canadian HIV Vaccine Initiative (CHVI) in 2007, Canadians have made many significant contributions towards the development of a safe, effective, affordable and globally accessible HIV vaccine. The Alliance Coordinating Office (ACO) is honored to have been a part of this journey through our support of Canadian researchers, companies, funding organization and our international partners on their quest to develop new and novel ideas and approaches to HIV vaccine development. We realize the journey is not over and further work is needed to achieve the end of AIDS. However, we remain hopeful and optimistic about the future.

The ACO will be closing its doors as the CHVI comes to an end on March 31, 2017. It has truly been our pleasure and honour to work with all of you these past five years. We thank you for all your hard work and dedication, and look forward to hearing about the results of ongoing studies, as well as future discoveries.

Thank you and we wish you all the best!